Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
Eur J Cancer
    January 2026
  1. SPATA A, Ribeiro JM, Vigneri P, Zambelli A, et al
    Comprehensive review of pregnancy associated breast cancer: Clinical features, molecular characteristics and novel therapies.
    Eur J Cancer. 2026;235:116230.
    >> Share

  2. VALDERRAMA NF, Morel LO, Mweze DT, Derangere V, et al
    Chemo-prAIdict Breast: A deep learning solution for predicting residual disease on biopsies of breast cancer patients treated with neoadjuvant chemotherapy.
    Eur J Cancer. 2026;234:116222.
    >> Share

  3. YAN Y, Xue X, Xie J, Liu J, et al
    Prediction of HER2 changes post-neoadjuvant therapy based on fusion of ultrasound radiomics and clinicopathological features empowered by explainable AI: A multicenter study.
    Eur J Cancer. 2026;232:116158.
    >> Share

    December 2025
  4. DIECI MV, Vernaci G, Colangelo C, Bria E, et al
    PIK3CA mutations and first-line outcomes in endocrine-resistant HR+/HER2- metastatic breast cancer: A multicentric real-world study.
    Eur J Cancer. 2025;234:116194.
    >> Share

  5. NICOLO E, Reduzzi C, Pierga JY, Gazzaniga P, et al
    International expert consensus on the clinical integration of circulating tumor cells in solid tumors.
    Eur J Cancer. 2025;231:116050.
    >> Share

  6. BOUTEILLER F, Gourgou S, Bringuier M, Galvin A, et al
    Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort.
    Eur J Cancer. 2025;233:116166.
    >> Share

  7. BORREGO MR, Lopez-Bravo DP, Vila MM, Perez-Garcia JM, et al
    Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study.
    Eur J Cancer. 2025;233:116161.
    >> Share

  8. PENAULT-LLORCA F, Lusque A, Filleron T, Tran K, et al
    Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score(R) in node-positive breast cancer: Independent validation in the PACS-01 trial.
    Eur J Cancer. 2025;233:116152.
    >> Share

    November 2025
  9. ZHANG R, Li H, Ding L, Liu H, et al
    Subvisual imaging signals as biomarkers of impending lung metastasis: A multicenter pan-cancer study.
    Eur J Cancer. 2025;230:116056.
    >> Share

  10. ZUO H, Vaihenberg E, Singh A, Bal G, et al
    Response to letter Re: Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation.
    Eur J Cancer. 2025;232:116113.
    >> Share

  11. WOOLPERT KM, Collin LJ, Cronin-Fenton DP
    Letter Re: Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation.
    Eur J Cancer. 2025;232:116112.
    >> Share

  12. BUONAIUTO R, Martorana F, Marino P, Mangiacotti F, et al
    Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancer.
    Eur J Cancer. 2025;232:116102.
    >> Share

  13. PUJOL P, Roca L, Lortholary A, Lasset C, et al
    Letrozole to prevent breast cancer in postmenopausal women with BRCA1/2 mutations (LIBER study).
    Eur J Cancer. 2025;231:116101.
    >> Share

  14. RASSY E, Delaloge S, Karimi M, Truong T, et al
    Evaluating breast cancer screening consortium and MammoRisk plus polygenic risk score 313 for breast cancer risk prediction in UK Biobank.
    Eur J Cancer. 2025;231:116096.
    >> Share

    October 2025
  15. SPOOR DS, Boekel NB, Leeuwen FEV, Russell N, et al
    Predicting acute coronary events after breast cancer radiotherapy: Integrating baseline cardiovascular risk, systemic therapy, and cardiac radiation dose in the MEDIRAD BRACE study.
    Eur J Cancer. 2025;231:116055.
    >> Share

  16. WORTELBOER N, Kent S, Konings IR, van Ommen-Nijhof A, et al
    Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial.
    Eur J Cancer. 2025;231:116051.
    >> Share

  17. BELCASTRO E, Marletta S, Tornabene I, Cinacchi P, et al
    MTClin: Integrating MammaTyper(R) to predict neoadjuvant therapy response in HER2+?breast cancer.
    Eur J Cancer. 2025;230:116049.
    >> Share

  18. SALFI G, Olivier T
    When suboptimal post-protocol care in oncology trials is rewarded.
    Eur J Cancer. 2025;228:115702.
    >> Share

    September 2025
  19. ZHANG S, Sun T, Wang X, Yan M, et al
    Efficacy and safety of MRG002 monotherapy in treating patients with locally advanced or metastatic breast cancer with low HER2 expression: A multi-center, non-randomized, open-label phase II clinical trial.
    Eur J Cancer. 2025;230:115794.
    >> Share

  20. ZUO H, Vaihenberg E, Singh A, Bal G, et al
    Response to Letter Re: Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation.
    Eur J Cancer. 2025;229:115781.
    >> Share

  21. MOUSTAQUIM J, van Wonderen GE, van Geel JJL, van Kruchten M, et al
    Comparative analysis of FES-PET/CT and FDG-PET/CT in patients with ER-positive metastatic invasive lobular breast cancer.
    Eur J Cancer. 2025;229:115792.
    >> Share

  22. HANVIC B, Joureau-Chabert A, Ouldbey Y, Toussaint P, et al
    Compression therapy with surgical gloves compared to cold therapy with frozen gloves in preventing paclitaxel-induced peripheral neuropathy: Results from the prospective ELEGANT trial in patients with breast cancer.
    Eur J Cancer. 2025;229:115791.
    >> Share

  23. WANG ZN, Tian GH, Ding JR, Lin Y, et al
    Acupuncture effect on brain default mode network connectivity in breast cancer patients with hot flashes: A randomized controlled trial.
    Eur J Cancer. 2025;229:115785.
    >> Share

  24. ALTUNDAG K
    Letter Re: Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation.
    Eur J Cancer. 2025;229:115780.
    >> Share

  25. HAYASHI T, Ogita M, Kakegawa R, Kikawa Y, et al
    Comparison of hypofractionation and conventional fractionation in postmastectomy radiotherapy after immediate breast reconstruction: A systematic review and meta-analysis of complications.
    Eur J Cancer. 2025;227:115669.
    >> Share

  26. AUTIER P, Jorgensen KJ, Stovring H
    Evaluation of screening mammography effectiveness: The IARC recommendations of 2015 need revision.
    Eur J Cancer. 2025;227:115657.
    >> Share

    August 2025
  27. VALENZA C, Curigliano G
    Positioning oral selective estrogen receptor degraders in patients with metastatic breast cancer.
    Eur J Cancer. 2025;228:115739.
    >> Share

  28. ALPERT A, Shirron N, Shirman Y, Goshen-Lago T, et al
    Deciphering the proteomic landscape of pregnancy-associated colorectal cancer.
    Eur J Cancer. 2025;228:115718.
    >> Share

  29. MICHEL LL, Ziegler P, Kreis P, Hartkopf AD, et al
    Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer.
    Eur J Cancer. 2025;227:115689.
    >> Share

    July 2025
  30. ZUO H, Vaihenberg E, Singh A, Bal G, et al
    Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation.
    Eur J Cancer. 2025;227:115665.
    >> Share

  31. GIORGI ROSSI P, Venturelli F
    Letter Re: Evaluation of screening mammography effectiveness: The IARC recommendations of 2015 need revision: Observational studies on breast cancer screening: different perspectives and questions require different approaches.
    Eur J Cancer. 2025;227:115659.
    >> Share

  32. DI MICCO R, Hartmann S, Banys-Paluchowski M, de Boniface J, et al
    Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients - Results from the prospective AXSANA registry trial.
    Eur J Cancer. 2025;226:115607.
    >> Share

    June 2025
  33. KNAUER M, Egle D, Hayoz S, Savolt A, et al
    Genomic profiling of primary tumor and lymph node metastasis in patients with clinically node-positive breast cancer: prospective cohort study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
    Eur J Cancer. 2025;225:115585.
    >> Share

    May 2025
  34. RUGGIERO E, Sharma S, Di Castelnuovo A, Costanzo S, et al
    Olive oil consumption and risk of breast cancer: Prospective results from the Moli-sani Study, and a systematic review of observational studies and randomized clinical trials.
    Eur J Cancer. 2025;224:115520.
    >> Share

  35. DI MICCO R, Botteri E, Canevari C, Gallivanone F, et al
    [(18)F]FDG PET/MRI vs sentinel node biopsy for axillary staging of early breast cancer patients. A prospective single-arm trial.
    Eur J Cancer. 2025;224:115519.
    >> Share

  36. DAUCCIA C, Alice Franzoi M, Martel S, Agbor-Tarh D, et al
    Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial.
    Eur J Cancer. 2025;223:115489.
    >> Share

  37. VAN KESSEL E, Woerdman N, Pluim D, Kerklaan BM, et al
    Added prognostic value of circulating tumor cell numbers in CSF of patients with leptomeningeal metastasis from epithelial tumors.
    Eur J Cancer. 2025;220:115377.
    >> Share

    April 2025
  38. DING N, Hermans KEPE, van Nijnatten TJA, Engelen SME, et al
    Overall survival of patients with de Novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: A population-based cohort study of systemically treated patients.
    Eur J Cancer. 2025;222:115475.
    >> Share

  39. BIGANZOLI G, Isnaldi E, Richard F, Marano G, et al
    Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial.
    Eur J Cancer. 2025;222:115438.
    >> Share

  40. MAGATON IM, Blondeaux E, Hamy AS, Linn S, et al
    Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study.
    Eur J Cancer. 2025;222:115434.
    >> Share

  41. DE PLACIDO P, Di Rienzo R, Pietroluongo E, Martinelli C, et al
    Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study.
    Eur J Cancer. 2025;221:115409.
    >> Share

  42. MIYAWAKI IA, Banerjee I, Batalini F, Campello Jorge CA, et al
    Global disparities in artificial intelligence-based mammogram interpretation for breast cancer: A scientometric analysis of representation, trends, and equity.
    Eur J Cancer. 2025;220:115394.
    >> Share

    March 2025
  43. BEDARD PL, Jhaveri KL, Accordino MK, Cervantes PA, et al
    Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study.
    Eur J Cancer. 2025;221:115397.
    >> Share

  44. BOTTOSSO M, Sandoval RL, Verret B, Polidorio N, et al
    Corrigendum to "HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome" [Eur J Cancer 211 (2024) 114307].
    Eur J Cancer. 2025 Mar 18:115370. doi: 10.1016/j.ejca.2025.115370.
    >> Share

  45. SIITONEN H, Joensuu J, Savolainen-Peltonen H, Gissler M, et al
    Update of the impact of menopausal hormone therapy on breast cancer risk.
    Eur J Cancer. 2025;220:115340.
    >> Share

    February 2025
  46. METZGER FILHO O, Cardoso F, Poncet C, Desmedt C, et al
    Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial.
    Eur J Cancer. 2025;217:115222.
    >> Share

  47. GRIGUOLO G, Bottosso M, Crema A, Giarratano T, et al
    Exceptional responses to systemic treatment in metastatic breast cancer: clinical features and long-term outcomes.
    Eur J Cancer. 2025;219:115321.
    >> Share

  48. STEGER K, Fiegl H, Feroz B, Leitner K, et al
    Differences in immunogenicity of TP53-mutated cancers with low tumor mutational burden (TMB) A study on TP53mut endometrial-, ovarian- and triple-negative breast cancer.
    Eur J Cancer. 2025;219:115320.
    >> Share

    January 2025
  49. COTTU P
    Identifying and managing adverse prognosis biomarkers among advanced luminal breast cancer patients: What have we learned?
    Eur J Cancer. 2025 Jan 10:115228. doi: 10.1016/j.ejca.2025.115228.
    >> Share

  50. HART LL, Im SA, Tolaney SM, Campone M, et al
    Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials.
    Eur J Cancer. 2025;217:115225.
    >> Share

  51. GIL QUESSEP E, van der Waal D, Peters J, Delaloge S, et al
    Subgroups varying in risk and density highlight the potential for stratified breast cancer screening.
    Eur J Cancer. 2025;217:115220.
    >> Share

  52. TOLOSA P, Pascual T, Martinez-Saez O, Hernando C, et al
    Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study.
    Eur J Cancer. 2025 Jan 3:115219. doi: 10.1016/j.ejca.2024.115219.
    >> Share

    December 2024
  53. DENNIS N, Dunton K, Livings C, Bogoeva N, et al
    Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial.
    Eur J Cancer. 2024;217:115192.
    >> Share

  54. NEVEN P, Han S, Verhoeven D, Soubry A, et al
    Letter re: Higher relative survival in breast cancer patients treated in certified and high-volume breast cancer centres - A population-based study in Belgium.
    Eur J Cancer. 2024 Dec 14:115166. doi: 10.1016/j.ejca.2024.115166.
    >> Share

  55. LEROY R, Bourgeois J, Canon JL, Carly B, et al
    Response to letter entitled: Re: Higher relative survival in breast cancer patients treated in certified and high-volume breast cancer centres - A population-based study in Belgium.
    Eur J Cancer. 2024 Dec 9:115167. doi: 10.1016/j.ejca.2024.115167.
    >> Share

  56. MILANO M, Valenza C, Ferrari A, Gandini S, et al
    Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer.
    Eur J Cancer. 2024;215:115164.
    >> Share

    November 2024
  57. MOLINELLI C, Bruzzone M, Blondeaux E, Ruelle T, et al
    The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study.
    Eur J Cancer. 2024;213:115113.
    >> Share

  58. ANKERSMID JW, Drossaert CHC, Strobbe LJA, Hackert MQN, et al
    Shared decision-making supported by outcome information regarding surveillance after curative treatment for breast cancer: Results of the SHOUT-BC study.
    Eur J Cancer. 2024;213:115107.
    >> Share

    October 2024
  59. LIVRAGHI L, Martella F, Ghilli M, Angiolini C, et al
    Prospective study on Oncotype DX(R) assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial.
    Eur J Cancer. 2024;213:115108.
    >> Share

  60. VALENZA C, Trapani D, Zagami P, Antonarelli G, et al
    Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study.
    Eur J Cancer. 2024;213:115097.
    >> Share

  61. ANTOINE A, Perol D, Robain M, Bachelot T, et al
    Assessing the real-world effectiveness of 8 major metastatic breast cancer drugs using target trial emulation.
    Eur J Cancer. 2024;213:115072.
    >> Share

  62. LEE DW, Ryu HS, Nikas IP, Koh J, et al
    Immune marker expression and prognosis of early breast cancer expressing HER3.
    Eur J Cancer. 2024;213:115081.
    >> Share

  63. VAN OMMEN-NIJHOF A, Steenbruggen TG, Wiersma TG, Balduzzi S, et al
    Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study.
    Eur J Cancer. 2024;213:115083.
    >> Share

    September 2024
  64. GANNON MR, Dodwell D, Miller K, Medina J, et al
    Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: A national population-based cohort study using routine data.
    Eur J Cancer. 2024;211:114309.
    >> Share

  65. BOTTOSSO M, Sandoval RL, Verret B, Polidorio N, et al
    HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome.
    Eur J Cancer. 2024;211:114307.
    >> Share

  66. BOTTA L, Capocaccia R, Bernasconi A, Rossi S, et al
    Estimating cure and risk of death from other causes of cancer patients: EUROCARE-6 data on head & neck, colorectal, and breast cancers.
    Eur J Cancer. 2024;208:114187.
    >> Share

  67. CHEN J, Yin Y, Li G, Tian H, et al
    Integrated nomogram to predict HER2 expression in breast tumor: Clinical, Ultrasound, and Photoacoustic imaging approaches.
    Eur J Cancer. 2024;209:114259.
    >> Share

    August 2024
  68. STEVENTON L, Kipps E, Man KK, Roylance R, et al
    The impact of inter-cycle treatment delays on 5-year all-cause mortality in early-stage breast cancer: A retrospective cohort study.
    Eur J Cancer. 2024;210:114301.
    >> Share

  69. DUBOEUF M, Amadou A, Coudon T, Grassot L, et al
    Long-term exposure to air pollution at residential and workplace addresses and breast cancer risk: A case-control study nested in the French E3N-Generations cohort from 1990 to 2011.
    Eur J Cancer. 2024;210:114293.
    >> Share

    July 2024
  70. FASCHING PA, Hack CC, Nabieva N, Maass N, et al
    Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole.
    Eur J Cancer. 2024;209:114239.
    >> Share

  71. LEROY R, Silversmit G, Bourgeois J, De Gendt C, et al
    Higher relative survival in breast cancer patients treated in certified and high-volume breast cancer centres - A population-based study in Belgium.
    Eur J Cancer. 2024;210:114232.
    >> Share

  72. DARBANDI MR, Darbandi M, Darbandi S, Bado I, et al
    Artificial intelligence breakthroughs in pioneering early diagnosis and precision treatment of breast cancer: A multimethod study.
    Eur J Cancer. 2024;209:114227.
    >> Share

  73. MARTINS-BRANCO D, Nader-Marta G, Molinelli C, Ameye L, et al
    Response to letter re: Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis.
    Eur J Cancer. 2024;208:114195.
    >> Share

    June 2024
  74. HASLAM A, Ranganathan S, Prasad V, Olivier T, et al
    CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms.
    Eur J Cancer. 2024;207:114192.
    >> Share

  75. CHEW SM, Ferraro E, Safonov A, Chen Y, et al
    Impact of cyclin dependent kinase 4/6 inhibitors on breast cancer brain metastasis outcomes.
    Eur J Cancer. 2024;207:114175.
    >> Share

  76. IGNATIADIS M, Poulakaki F, Spanic T, Brain E, et al
    EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe.
    Eur J Cancer. 2024;207:114156.
    >> Share

    May 2024
  77. HAN W, Zhang DD, Zhang YW, Shi LZ, et al
    Letter re: Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2024 May 22:114126. doi: 10.1016/j.ejca.2024.114126.
    >> Share

    April 2024
  78. GUERINI-ROCCO E, Bellerba F, Concardi A, Taormina SV, et al
    Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ.
    Eur J Cancer. 2024;203:114063.
    >> Share

  79. COLOMBO I, Koster KL, Holer L, Haefliger S, et al
    TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
    Eur J Cancer. 2024;201:113588.
    >> Share

  80. BARTELS SAL, van Olmen JP, Scholten AN, Bekers EM, et al
    Real-world data on malignant and borderline phyllodes tumors of the breast: A population-based study of all 921 cases in the Netherlands (1989 -2020).
    Eur J Cancer. 2024;201:113924.
    >> Share

    March 2024
  81. ROUSSOT N, Constantin G, Desmoulins I, Bergeron A, et al
    Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
    Eur J Cancer. 2024;202:114037.
    >> Share

  82. UNTCH M, Perol D, Mayer EL, Cortes J, et al
    Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis.
    Eur J Cancer. 2024;202:113977.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016